These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 10622327)

  • 1. Escherichia coli for ulcerative colitis.
    Langman MJ; Allan RN
    Lancet; 1999 Dec; 354(9194):2000-1. PubMed ID: 10622327
    [No Abstract]   [Full Text] [Related]  

  • 2. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
    Adam B; Liebregts T; Holtmann G
    Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ulcerative colitis. Acute episode].
    Reissmann A; Bischoff SC; Fleig W
    Z Gastroenterol; 2004 Sep; 42(9):994-8. PubMed ID: 15455271
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
    Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
    Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the optimal maintenance treatment for ulcerative colitis?
    Cohen RD
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S236-7. PubMed ID: 18816679
    [No Abstract]   [Full Text] [Related]  

  • 6. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    Harbord M; Eliakim R; Bettenworth D; Karmiris K; Katsanos K; Kopylov U; Kucharzik T; Molnár T; Raine T; Sebastian S; de Sousa HT; Dignass A; Carbonnel F;
    J Crohns Colitis; 2017 Jul; 11(7):769-784. PubMed ID: 28513805
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
    Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How important is mesalamine in the maintenance of steroid-refractory colitis?
    Actis GC; Marzano A; Pellicano R; Rizzetto M
    Inflamm Bowel Dis; 2008 Jul; 14(7):1026. PubMed ID: 18338772
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment and recurrence prevention ulcerative colitis].
    Schölmerich J
    Internist (Berl); 1995 Dec; 36(12):1124-32. PubMed ID: 8567217
    [No Abstract]   [Full Text] [Related]  

  • 10. [Probiotics in chronic inflammatory bowel disease].
    Böhm S; Kruis W
    MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hair of the dog.
    Bahrani O
    Am J Gastroenterol; 2001 Sep; 96(9):2789-90. PubMed ID: 11569714
    [No Abstract]   [Full Text] [Related]  

  • 12. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
    Folwaczny C
    Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
    [No Abstract]   [Full Text] [Related]  

  • 13. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
    Faubion WA; Sandborn WJ
    Gastroenterology; 2000 Mar; 118(3):630-1. PubMed ID: 10702217
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management of ulcerative colitis].
    Rammert Ch; Kullak-Ublick GA
    Ther Umsch; 2003 Mar; 60(3):145-50. PubMed ID: 12693317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
    Regueiro M; Loftus EV; Steinhart AH; Cohen RD;
    Inflamm Bowel Dis; 2006 Oct; 12(10):972-8. PubMed ID: 17012968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.
    Garcia-Planella E; Mañosa M; Van Domselaar M; Gordillo J; Zabana Y; Cabré E; López San Román A; Domènech E
    Dig Liver Dis; 2012 Mar; 44(3):206-10. PubMed ID: 22079262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inflammatory diseases of the intestines].
    Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
    Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory bowel disease.
    Podolsky DK
    N Engl J Med; 2002 Aug; 347(6):417-29. PubMed ID: 12167685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.